Overview
Belgium medical tech firm's preliminary Q4 net revenue rises, beating analyst expectations
Company trained 145 surgeons on Genio system, activated 57 U.S. accounts
Outlook
Nyxoah expects U.S. net revenue to grow by 25% in Q1 2026
Company anticipates international revenue to follow typical seasonal patterns
Result Drivers
U.S. COMMERCIALIZATION - Nyxoah's first full quarter of U.S. commercialization post-FDA approval drove significant revenue growth, with U.S. net revenue reaching €3.5 million
SURGEON TRAINING - Company trained 145 surgeons and activated 57 accounts in the U.S., supporting growth in Genio system adoption
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
EUR 5.70 mln
EUR 3.90 mln (6 Analysts)
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Nyxoah SA is €9.75, about 121.8% above its January 12 closing price of €4.40
Press Release: ID:nGNE88xS7G
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)